Retham Technologies
Biotechnology, 1225 Discovery Pkwy, Milwaukee, Wisconsin, 53226, United States, 1-10 Employees
Phone Number: +14*********
Who is RETHAM TECHNOLOGIES
Retham TechnologiesTM LLC was established in 2017 to translate recent discoveries into a life-saving in vitro diagnostic (IVD) assay that provides earlier and more accurate in-hospital di...
Read More
- Headquarters: 1225 Discovery Pkwy, Milwaukee, Wisconsin, 53226, United States
- Employees: 1-10
- Revenue: Under $1 Million
Industry: Biotechnology
SIC Code: 2836 | NAICS Code: 541714 | Show More
Does something look wrong? Fix it. | View contact records from RETHAM TECHNOLOGIES
Retham Technologies Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Retham Technologies
Answer: Retham Technologies's headquarters are located at 1225 Discovery Pkwy, Milwaukee, Wisconsin, 53226, United States
Answer: Retham Technologies's phone number is +14*********
Answer: Retham Technologies's official website is https://rethamtechnologies.com
Answer: Retham Technologies's revenue is Under $1 Million
Answer: Retham Technologies's SIC: 2836
Answer: Retham Technologies's NAICS: 541714
Answer: Retham Technologies has 1-10 employees
Answer: Retham Technologies is in Biotechnology
Answer: Retham Technologies contact info: Phone number: +14********* Website: https://rethamtechnologies.com
Answer: Retham TechnologiesTM LLC was established in 2017 to translate recent discoveries into a life-saving in vitro diagnostic (IVD) assay that provides earlier and more accurate in-hospital diagnosis of Heparin-induced Thrombocytopenia (HIT). HIT is a serious adverse reaction to the blood thinner heparin. It is characterized by a drop in platelet count (thrombocytopenia) and in ~1/3rd of cases, causes blood clotting (thrombosis) that can result in life-and-limb threatening consequences such as amputation, stroke and death. The diagnosis of HIT is challenging. A family of easy-to-run tests called PF4 ELISAs is performed in the hospital laboratory but have high false positive rates, i.e. many patients positive for antibodies to PF4:polyanion complexes do not have clinical HIT. A second test, the Serotonin release assay (SRA), is considered the gold-standard test for HIT; but, it is performed only at a handful of laboratories nationally on a small fraction of suspected cases due to technical complexity, cost and turnaround time concerns. Thus, >90% of HIT suspected patients are currently managed using PF4 ELISAs, and thousands of patients receive costly non-heparin anticoagulant therapy due to false positive diagnoses. These alternative anticoagulants have a worse bleeding risk profile relative to heparin often resulting in severe or fatal hemorrhage. Retham TechnologiesTM is developing HITDxTM, an IVD assay for early and accurate near-patient HIT diagnosis that is expected to facilitate timely and appropriate therapy thereby leading to better outcomes.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month